Addition of nifedipine to maximal beta-blocker-nitrate therapy: Effects on exercise capacity and global left ventricular performance at rest and during exercise-Reference-Cited by-同舟云学术

Addition of nifedipine to maximal beta-blocker-nitrate therapy: Effects on exercise capacity and global left ventricular performance at rest and during exercise

Published:1985-05 Issue:12 Volume:55 Page:E3-E8
ISSN:0002-9149
Container-title:The American Journal of Cardiology
language:en
Short-container-title:The American Journal of Cardiology

Author:

Nesto Richard W,White Harvey D,Ganz Peter,Koslowski Joseph,Wynne Joshua,Holman B.Leonard,Antman Elliot

Publisher

Elsevier BV

Subject

Cardiology and Cardiovascular Medicine

Reference35 articles.

1. Propranolol and isosorbide dinitrate synergism in angina pectoris;Russek;Am J Cardiol,1968

2. Calcium channel blocking agents in the treatment of cardiovascular disorders. II. Hemodynamic effects and clinical applications;Stone;Ann Intern Med,1980

3. Clinical and circulatory effects of isosorbide dinitrate: comparison with nitroglycerin;Goldstein;Circulation,1971

4. Sustained hemodynamic and antianginal effect of high dose oral isosorbide dinitrate;Danahy;Circulation,1977

5. Propranolol in patients with angina pectoris;Gianelly;Ann Intern Med,1967

Cited by 26 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Measuring antianginal drug efficacy using exercise testing for chronic angina: Improved exercise peformance with ranolazine, a pFOX inhibitor;CURR PROB CARDIOLOGY;2002

2. Measuring antianginal drug efficacy using exercise testing for chronic angina: Improved exercise peformance with ranolazine, a pFOX inhibitor;Current Problems in Cardiology;2002-12

3. Monotherapy with amlodipine or atenolol versus their combination in stable angina pectoris;Clinical Cardiology;2000-10

4. The Calcium Antagonist Controversy: The Emerging Importance of Drug Formulation as a Determinant of Risk;The American Journal of Cardiology;1997-05

5. Calcium antagonists: Still appropriate as first line antihypertensive agents;American Journal of Hypertension;1996-02